Meena Alnajar is an IPilogue Writer, IP Innovation Clinic Fellow, and a 2L JD Candidate at Osgoode Hall Law School. Leaves may be falling in time for autumn, but…
Category: Access to Medicines
Insulin Biohackers: Shaking Up a Billion-Dollar Industry
Natalie Bravo is an IPilogue Writer and a 2L JD Candidate at Osgoode Hall Law School. Brief History of Insulin In 1921, Dr. Frederick Banting, Charles Best, and James…
Biden Support for Covid-19 Intellectual Property Waiver: A Step Below Progress?
Ryan Erdman is an IPilogue Writer and a 2L JD Candidate at Osgoode Hall Law School. In a truly monumental achievement in scientific innovation, there are now over a dozen authorized COVID-19…
in Access to Medicines, Blogs, Commercialization, Development, Innovation, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
1075
Broken Promises: Utility Standards and Patent Applications in Canada
The last day of June 2017 saw the Supreme Court of Canada (SCC) quash the controversial Promise Doctrine. The issue at hand in AstraZeneca Canada Inc v Apotex Inc was…
in Access to Medicines, Commercialization, Design, Development, IP, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
1612
What Makes It My Molecule: A Look at Professor Ronald Pearlman’s Genome Editing Work
This past November, Professor Ronald E. Pearlman from York University’s Department of Biology gave a talk [1] at Osgoode Hall Law School to discuss the potential of the innovative CRISPR…
Breaking the Fall Off the Patent Cliff: Can Developing Countries Help Big Pharma?
Expiring patents are expected to contribute billions of dollars towards the loss of revenue of drug manufacturers in the years to come. To save itself from falling off the patent cliff,…